A review of the flortaucipir literature for positron emission tomography imaging of tau neurofibrillary tangles.

ABSTRACT: Alzheimer's disease is defined by the presence of β-amyloid plaques and neurofibrillary tau tangles potentially preceding clinical symptoms by many years. Previously only detectable post-mortem, these pathological hallmarks are now identifiable using biomarkers, permitting an in vivo definitive diagnosis of Alzheimer's disease. ¹⁸F-flortaucipir (previously known as ¹⁸F-T807; ¹⁸F-AV-1451) was the first tau positron emission tomography tracer to be introduced and is the only Food and Drug Administration-approved tau positron emission tomography tracer (Tauvid™). It has been widely adopted and validated in a number of independent research and clinical settings. In this review, we present an overview of the published literature on flortaucipir for positr

SUBMITTER: Burnham SC 

PROVIDER: S-EPMC10768888 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature